Income Statement (TTM)
Design Therapeutics, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
|
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Change (%) | -62.83 | -36.90 | -37.74 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 6 | 10 | 14 | 20 |
| Change (%) | 57.72 | 41.49 | 48.99 | |
| % of Revenue | 2,681.42 | 11,378.57 | 25,516.98 | 61,057.58 |
| Gross Operating Profit | -6 | -9 | -13 | -20 |
| Change (%) | 62.39 | 42.19 | 49.33 | |
| % of Revenue | -2,581.42 | -11,278.57 | -25,416.98 | -60,957.58 |
| SG&A | 2 | 4 | 6 | 8 |
| Change (%) | 56.77 | 56.91 | 37.61 | |
| % of Revenue | 1,104.42 | 4,658.33 | 11,584.91 | 25,603.03 |
| R&D | ||||
| Change (%) | ||||
| % of Revenue | ||||
| OpEx | 9 | 13 | 20 | 29 |
| Change (%) | 57.45 | 45.97 | 45.43 | |
| % of Revenue | 3,785.84 | 16,036.90 | 37,101.89 | 86,660.61 |
| Operating Income | -8 | -13 | -20 | -29 |
| Change (%) | 60.71 | 46.49 | 45.66 | |
| % of Revenue | -3,685.84 | -15,936.90 | -37,001.89 | -86,560.61 |
| Interest Expense | ||||
| Change (%) | ||||
| % of Revenue | ||||
| Net Income | -8 | -13 | -19 | -28 |
| Change (%) | 58.59 | 47.17 | 46.56 | |
| % of Revenue | -3,663.72 | -15,632.14 | -36,462.26 | -85,827.27 |
Source: Capital IQ
